“…Rheumatoid arthritis (RA) is a systemic autoimmune disease dominated by persistent inflammatory lesions of joint tissue, with a global incidence rate of about 1%. , As a progressive joint disease, RA can cause discomfort, pain, joint damage, disability, and even death. , Although the exact cause of RA pathogenesis is unknown, one of the key processes is the aberrant activation of CD4 + T cells and the imbalance of Th17/Treg, which break self-tolerance, causing persistent synovitis and gradual degradation of cartilage and subchondral bone. , At present, the clinical treatments for RA involve the use of systemic immune suppressants, either by inhibiting inflammation or by depleting specific immune cells and pro-inflammatory factors. , These treatments can delay the progression and alleviate symptoms of RA, but long-term and high-dose use of these drugs can easily lead to systemic immunosuppression, which can induce opportunistic infections or increase the risk of tumors. , Therefore, developing a novel effective approach is highly desired to improve the therapeutic efficiency of RA and minimize the side effect.…”